

Technology Advisory Committee D Interests Register

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [ID3835]

Publication Date: 19 January 2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Ivan Koychev	Committee Member	Professional	Dr Koychev was recently awarded an NIHR fellowship which will be done in collaboration with AstraZeneca. The work will focus on non-oncological compounds for the treatment of Alzheimer's disease.	N/A	25.06.2021	N/A	It was agreed that his declaration would not prevent Dr Koychev from participating in discussions on this appraisal.
Dr Ed Wilson	Committee member	Financial	AstraZeneca are clients of Dr Wilson's company, but they have not worked on osimertinib.	N/A	18.08.2021	N/A	It was agreed that his declaration would not prevent Dr Wilson from participating in discussions on this appraisal.
Dr Gary Doherty	Clinical expert	Financial	Dr Doherty has received speaker honoraria and consultancy fees from Amgen, AstraZeneca, Boehringer Ingelheim, Bayer, MSD, Novartis, Roche, Pfizer and Merck.	N/A	21.01.2021 14.07.2021	N/A	It was agreed that his declarations would not prevent Dr Doherty from providing expert advice to the committee.

Professor Eric Lim	Clinical expert	Financial	Professor Lim has received personal fees from AstraZeneca for advisory board, meetings and education, and grants and personal fees from Abbott Molecular, Glaxo Smith Kline, Pfizer, Novartis, Medtronic / Covidien, Roche, Lily Oncology, Boehringer Ingelheim, Medela, ScreenCell, Johnson and Johnson / Ethicon, Clearbridge Biomedics, Illumina, Guardant Health, and BMS. He also has a patent (P57988GB) relating to blood-based EGFR testing issued to Imperial Innovations.	N/A	21.01.2021	N/A	It was agreed that his declarations would not prevent Professor Lim from providing expert advice to the committee.
Dr Andrew Robinson	Clinical expert	Financial	Dr Robinson received payment from AstraZeneca for a speaking engagement regarding impacts of COVID in histopathology in November 2020. Dr Robinson will also receive honorarium for giving a presentation on June 30 2021.	N/A	13.01.2021 14.07.2021	N/A	It was agreed that his declarations would not prevent Dr Robinson from providing expert advice to the committee.